Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Aiforia Technologies

0.92 EUR-1.92 %16.10. klo 18.29
2,233 following

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-1.92 %
+2.79 %
-48.78 %
-44.17 %
-63.05 %
-65.93 %
-75.07 %
-
-81.82 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
34.42M EUR
Turnover
5.62K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Reduce
Target price
Updated
31.08.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Aiforia Enters into Collaboration with PathAI to Expand Access to AI-Powered Diagnostics Aiforia Enters into Collaboration with PathAI to Expand Access to AI-Powered Diagnostics Aiforia Technologies Plc, Press Release, October 8, 2026, at 09:00 a.m. Aiforia, a pioneer in pathology...
10/8/2026, 6:09 AM
by Kulkuri
30
Comments on the latest move LinkedIn #digitalpathology #ai #lifesciences #diagnostics | Paul Atkinson First Roche and PathAI. Now Agilent Technologies and Proscia. 👀 When two of the biggest players in diagnostics make major bets on AI pathology within months of each other, that’s...
10/14/2026, 7:27 AM
by Vino Pino
16
Here are Antti’s comments regarding the acquisition of Aiforia’s partner by Agilent, a US-based laboratory and diagnostics company. The cash purchase price is 240 MUSD, with an additional earnout of up to 30 MUSD payable to the sellers. The acquisition continues the industry consolidation...
10/14/2026, 4:51 AM
by Sijoittaja-alokas
16
Domestic award for Aiforia: Messukeskuksessa juhlittiin suomalaisia maailmanluokan tekoälyratkaisuja – Opetushallitus ja Aiforia nappasivat Vuoden digiteko -palkinnot | Kauppalehti The winner of the corporate category, Aiforia, has harnessed artificial intelligence to assist pathologists...
10/8/2026, 6:27 PM
by NukkeNukuttaja
16
In my opinion, the CEO holds their own quite well in this panel. Sure, this industry is still pretty much in its infancy, but before you know it, we’re all grown up, mourning why we didn’t make the most of those childhood years.
10/1/2026, 11:52 AM
by Salvelinus
12
Looks like Zeroman Oy has also jumped on the Aiforia bandwagon, and Laakkonen added significantly—I guess these can be counted as positive signs.
10/1/2026, 4:39 AM
by Salvelinus
12
thepathologist.com The Pathologist | Pathology Visions 2026 – Digital Pathology Conference Aiforia will also be featured there in a few days. Perhaps there will be some bigger news regarding Aiforia soon, as it has been so quiet and insiders haven’t been buying shares either, even...
10/14/2026, 5:53 AM
by Salvelinus
11
Read more on our forum
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 31.08.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Aiforia's partner Proscia acquired by Agilent
Analyst Comment14.10.2026 klo 09.39 by
Antti Siltanen

Aiforia's partner Proscia acquired by Agilent

Two of Aiforia's key platform partners are now owned by large corporations.

Aiforia Technologies
Aiforia enters into an agreement with PathAI
Analyst Comment09.10.2026 klo 08.05 by
Antti Siltanen

Aiforia enters into an agreement with PathAI

The partnership expands the distribution network in the US and thus supports our growth estimates.

Aiforia Technologies
Press release08.10.2026 klo 09.00

Aiforia collaborates with PathAI to broaden access to AI-driven diagnostics

Aiforia Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release24.09.2026 klo 10.15

Aiforia Technologies Plc: Share subscriptions based on stock options 2016B

Aiforia Technologies
Third party research02.09.2026 klo 09.08

Aiforia Technologies: H1'26 review: costs above expectations; est. & PT chg. - NuWays AG Research

Aiforia published its H1'26 report last Friday. Revenue of € 0.75m (-46% yoy) was already knownfrom the July profit warning, which we attributed to the absence of onboarding revenue and a slower than expected usage ramp up of existing clinical clients...

Aiforia Technologies
Aiforia H1'26: Still a long way to go before reaching profitability
Research31.08.2026 klo 14.26 by
Antti Siltanen, Antti Luiro

Aiforia H1'26: Still a long way to go before reaching profitability

Earnings fell short of our expectations due to both a one-off expense and a more permanent increase in the cost structure.

Aiforia Technologies
Aiforia, Webcast, Q2'26
Webcast28.08.2026 klo 10.00

Aiforia, Webcast, Q2'26

Aiforia Technologies
Regulatory press release28.08.2026 klo 09.00

Aiforia’s Half-Year Financial Report January-June 2026: Financing arrangements and new customers support future growth, revenue remained below the comparison period's level

Aiforia Technologies
Aiforia lands new partnership in breast cancer diagnostics
Analyst Comment26.08.2026 klo 10.59 by
Antti Siltanen

Aiforia lands new partnership in breast cancer diagnostics

The new partnership brings predictive risk profiling into diagnostics and can reduce the need for expensive genetic tests.

Aiforia Technologies
Aiforia H1'26 preview: Profit warning increased concerns about commercial progress
Analyst Comment26.08.2026 klo 13.00 by
Antti Siltanen

Aiforia H1'26 preview: Profit warning increased concerns about commercial progress

Contract delays caused H1 revenue to collapse to 0.75 MEUR and increased concerns about commercial performance.

Aiforia Technologies
Press release25.08.2026 klo 09.30

Aiforia and Stratipath partner to expand access to AI-driven precision diagnostics in oncology

Aiforia Technologies
Press release19.08.2026 klo 08.00

Aiforia to publish January–June 2026 Half-Year Financial Report on August 28, 2026

Aiforia Technologies
Aiforia secured a 20 MEUR financing agreement with the EIB
Analyst Comment03.08.2026 klo 09.19 by
Antti Siltanen, Antti Luiro

Aiforia secured a 20 MEUR financing agreement with the EIB

The loan arrangement secures financing for the coming years, provided the business develops favorably.

Aiforia Technologies
Regulatory press release31.07.2026 klo 18.00

Aiforia and the European Investment Bank have signed an agreement for EUR 20 million venture debt financing

Aiforia Technologies
Regulatory press release24.07.2026 klo 11.00

Aiforia Technologies Plc – Managers’ Transactions – Jukka Tapaninen

Aiforia Technologies
Third party research23.07.2026 klo 10.04

Aiforia Technologies: Aiforia H1 profit warning triggers downgrade to HOLD - NuWays AG Research

Aiforia issued a profit warning with H1'26 revenues coming in at a mere € 0.75m, down from € 1.4m in H1'25 (-46% yoy), against our expectation of roughly doubling yoy, following last year's strong Clinical momentum (organic growth of +65%). At the same...

Aiforia Technologies
Aiforia: We diagnose a growth deficiency
Research23.07.2026 klo 10.25 by
Antti Siltanen

Aiforia: We diagnose a growth deficiency

The ongoing uncertainty regarding growth is causing us to take a negative view of the risk-reward ratio.

Aiforia Technologies
Aiforia's H1 revenue was surprisingly subdued
Analyst Comment22.07.2026 klo 09.05 by
Antti Siltanen

Aiforia's H1 revenue was surprisingly subdued

The conversion of customer wins into revenue continues to be slow.

Aiforia Technologies
Regulatory press release21.07.2026 klo 18.40

Inside information, profit warning: Aiforia's revenue developed below the estimates during January–June 2026

Aiforia Technologies
Regulatory press release06.07.2026 klo 09.00

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies